<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00284778</url>
  </required_header>
  <id_info>
    <org_study_id>I05026</org_study_id>
    <nct_id>NCT00284778</nct_id>
  </id_info>
  <brief_title>Pharmaco-economic Study of a Second Line Treatment in Advanced Non Small Cell Lung Cancer</brief_title>
  <official_title>A Randomized Cost-minimization Trial Comparing Pemetrexed (Alimta®) Versus Docetaxel (Taxotere®) as Second Line Treatment in Advanced Non Small Cell Lung Cancer (NSCLC): Study 05-06 of Groupe Français de Pneumo-Cancérologie (GFPC).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Groupe Francais De Pneumo-Cancerologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <brief_summary>
    <textblock>
      The indication of chemotherapy of 2nd line treatment in advanced non small cell lung cancer
      is now well established. The two treatments of reference are pemetrexed (alimta) and
      docetaxel (taxotere). Effectiveness and toxicity of the two drugs are largely documented in
      the literature.

      Economic analyses are currently one of the criteria used in medical decision, beside
      effectiveness, quality of life and toxicities.

      However, Economical comparison shows significant variations in the acquisition costs of the
      two drugs. Consequently, it appears interesting to carry out a randomized prospective study
      with on exclusive economical criteria of judgment.

      As there is no difference in the effectiveness between the two treatments, a
      cost-minimization analysis will be carried out to appreciate the ratio benefit/risks from an
      economical point of view (payer).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of this trial is of to compare, economically, the use of pemetrexed
      (alimta®) in 2nd line chemotherapy in advanced non-small cell lung cancer versus docetaxel
      (taxotere®).

      150 patients will be selected for this trial which, after checking the eligibility criteria,
      will be randomized in two arms:

        -  Arm A: Taxotere 75 mg/m² every 3 weeks.

        -  Arm B : Alimta 500 mg/m² every 3 weeks.

      Inclusion assessment.

        -  Clinical signs

        -  Blood cell count, renal and hepatic function (within 8 days)

        -  Chest X ray, CT scan or MRI scan, abdominal echography, and/or abdominal scan (within 28
           days)

        -  Brain scan, bone scintigraphy and/or bone x ray (within 28 days)

        -  Bronchial endoscopy (within 28 days)

        -  EKG, echocardiography according to history

      Follow-up assessment.

        1. At each cycle

             -  Clinical signs

             -  Blood cell count at D1, D8, D15

             -  Creatinine, serum electrolytes (K+, Ca++ ), SGOT, SGPT, total bilirubin, LDH,
                alkaline phosphate, total protein and albumin, EKG, Chest X-ray at D1

        2. Follow-up each 2 months till PD

        3. End of trial: Complete tumor assessment

        4. Each objective response may be confirm 4 weeks later

      Length ot the study.

        -  Patients in each arm will be treated until progression or toxicity or decision to stop
           the trial.

        -  Responder patient will be treated until 6 cycles. The follow-up assessment will be
           carried out each 2 months.

      Response assessment. According to RECIST criteria.

      Resource consumption.

        1. Recording of volumes:

             -  All the medication quantities will be recorded in mg. The chemotherapeutic products
                will be recorded in mg. All the concomitant treatments : RHO, anti-emetics, growth
                factors, antibiotics or adverse event treatments will be notified.

             -  Hospitalizations for treatment and their categories ( inpatient, outpatient, home
                based treatment) will be noted.

             -  All the hospitalizations for adverse events will be recorded (and their category).
                Grade 1-2 adverse events will be notified in the case report form. Hospitalizations
                for disease complications or progressions, curative or palliative radiation will be
                recorded.

        2. Cost calculation :

             -  All hospitalisations will be valued by DRGs or day hospitalisation prices,
                according to the country. Ambulatory care will be valued by appropriate country
                prices. The drug price will be done by pharmaceutical companies.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alimta®</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Taxotere®</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically proved stage IV or pleural stage III NSCLC (neoplastic
             pleurisy confirmed).

          -  Metastatic relapses allowed if asymptomatic.

          -  Progressive disease during or after a standard first line platinum-based chemotherapy
             (without taxotere or alimta)

          -  Only one chemotherapeutic line including adjuvant and neo adjuvant treatment.

          -  Irradiation allowed if &lt; 25% bone medulla . It may be ended 2 weeks before the second
             line treatment.

          -  At least one measurable target lesion according to recist criteria in non previously
             irradiated area.

          -  Performance status &lt;=2

          -  Age between 18 and 70 years

          -  Life expectancy &gt; 12 weeks.

          -  Normal hepatic function

          -  Normal renal function

          -  Normal serum calcium

          -  Absolute neutrophil count&gt;1.5 gigal/l,platelets&gt;100 gigal/l,haemoglobin&gt;9.0 g/dl

          -  Written informed consent

        Exclusion Criteria:

          -  SCLC, bronchioli-alveolar and neuro-endocrine carcinoma.

          -  Symptomatic brain metastases.

          -  Superior vena cava syndrome.

          -  Uncontrolled fluid retention in the third space (pleural or ascitic collection)

          -  Prior chemotherapy without platin

          -  Other concomitant diseases: heart failure, angina pectoris, tachyarrythmia, recent
             myocardial infarction, active infections.

          -  Peripheral neuropathy grade ≥ 2.

          -  Past or concomitance of another cancer except baso-cellular carcinoma of the skin or
             in situ cervical carcinoma.

          -  Hypersensitivity to docetaxel or polysorbate 80.

          -  Unability or unwillingness to take folic acid, vitamin B12 supplementation or
             corticosteroids.

          -  Pregnancy or breast feeding.

          -  Follow-up of the patient impossible.

          -  Prisoners
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alain Vergnenegre, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Limoges</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christos Chouaid, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hôpital Saint Antoine; Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service de Pneumologie, CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de pneumologie; Centre Hospitalier d'Annecy</name>
      <address>
        <city>Annecy</city>
        <zip>74011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie; Centre Hospitalier</name>
      <address>
        <city>Beauvais</city>
        <zip>60 021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie ; Centre hospitalier</name>
      <address>
        <city>Charleville-Mezieres</city>
        <zip>08 000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie; Centre Hospitalier</name>
      <address>
        <city>Draguignan</city>
        <zip>83300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pathologie Respiratoire; CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie; Hôpital de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69317</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie-Neurologie ; Centre Hospitalier F. Quesnay</name>
      <address>
        <city>Mantes La Jolie</city>
        <zip>78200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Département des Maladies Respiratoires ; Hôpital Sainte Marguerite</name>
      <address>
        <city>Marseille</city>
        <zip>13274</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie et Réanimation ; Hôpital Hôtel Dieu - Paris</name>
      <address>
        <city>Paris</city>
        <zip>75181</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie - Hôpital St Antoine, Paris</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie ; Hôpital saint Antoine, Paris</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie-Allergologie; Centre Hospitalier Général</name>
      <address>
        <city>Perigueux</city>
        <zip>24019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie; CHG de Roanne</name>
      <address>
        <city>Roanne</city>
        <zip>42300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pneumologique; Hôpital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie; Hôpital Bois Guillaume</name>
      <address>
        <city>Rouen</city>
        <zip>76233</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pathologie Respiratoire; Hôpital d'Instruction des Armées Sainte-Anne</name>
      <address>
        <city>Toulon Naval</city>
        <zip>83800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Médicale; Clinique Sainte Marguerite</name>
      <address>
        <city>Toulon</city>
        <zip>83000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2006</study_first_submitted>
  <study_first_submitted_qc>January 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2006</study_first_posted>
  <last_update_submitted>March 26, 2010</last_update_submitted>
  <last_update_submitted_qc>March 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 29, 2010</last_update_posted>
  <responsible_party>
    <name_title>Marie SENGELEN</name_title>
    <organization>CHU LImoges</organization>
  </responsible_party>
  <keyword>lung cancer</keyword>
  <keyword>second line treatment</keyword>
  <keyword>cost-minimization trial</keyword>
  <keyword>Pharmaco-economic study</keyword>
  <keyword>docetaxel</keyword>
  <keyword>pemetrexed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

